ALPS Group Inc (NASDAQ:ALPS)
| Market Cap | 66.56M-96.7% |
| Revenue (ttm) | 3.37M |
| Net Income | -67.57M-6806.2% |
| EPS | -0.41-8772.2% |
| Shares Out | 166.40M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 61,129 |
| Open | 0.40 |
| Previous Close | 0.40 |
| Day's Range | 0.39 - 0.40 |
| 52-Week Range | 0.23 - 2.90 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
No insider has filed an open-market purchase or sale here in the last 90 days, so there is nothing to score yet.
About ALPS
Alps Group Inc. operates as a comprehensive biotechnology firm, delivering a wide array of services ranging from groundbreaking research and development to direct medical care and health optimization initiatives, with a primary focus on cutting-edge therapeutic solutions. The organization is committed to cultivating a just and balanced healthcare system, ensuring broad availability of early detection, disease prevention, and individualized treatment approaches.
$ALPS stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in ALPS holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by ALPS's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
ALPS Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New ALPS patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to ALPS from public contracts
Source: USAspending.gov
ALPS Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from ALPS’s recent data — informational, not investment advice
Recent Insider Activity
No Form 4 filings in the last 90 days.